# pancreatic ductal adenocarcinoma FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/pancreatic-ductal-adenocarcinoma

> 2 upcoming FDA catalysts in pancreatic ductal adenocarcinoma: navlimetostat (BMY) on May to Aug 2029 (topline data readout); navlimetostat (BMY) on May 2029 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Feb 2025 | [Autogene trial start](https://sec-api.dev/pdufa/autogene) | BNTX | pancreatic ductal adenocarcinoma | completed | "In February 2025, a manuscript denoting follow up data from an investigator-initiated Phase 1 clinical trial (NCT04161755, Rojas et al., 2023) evaluating autogene cevumeran in combination with atezolizumab in patients with pancreatic ductal adenocarcinoma ("PDAC") in an adjuvant treatment setting was published in Nature (Sethna et al., 2025)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1776985/000177698525000011/ex99250310_bntxxprxq42024x.htm)) |
| June 2026 | [OT-101 primary completion](https://sec-api.dev/pdufa/ot-101) | OTLC | Pancreatic Ductal Adenocarcinoma | delayed | "NCT06079346 (A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-06-01 (ESTIMATED); Lead Sponsor Oncotelic Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06079346)) |
| May to Aug 2029 | [Navlimetostat topline data readout](https://sec-api.dev/pdufa/navlimetostat) | BMY | Pancreatic Ductal Adenocarcinoma | scheduled | "NCT07076121 (A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-05-03 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07076121)) |
| May 2029 | [Navlimetostat primary completion](https://sec-api.dev/pdufa/navlimetostat) | BMY | Pancreatic Ductal Adenocarcinoma | scheduled | "NCT07076121 (A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-05-03 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07076121)) |

## Drugs

- [Autogene](https://sec-api.dev/pdufa/autogene) (BNTX)
- [OT-101](https://sec-api.dev/pdufa/ot-101) (OTLC)
- [Navlimetostat](https://sec-api.dev/pdufa/navlimetostat) (BMY)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/pancreatic-ductal-adenocarcinoma.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "pancreatic ductal adenocarcinoma FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/pancreatic-ductal-adenocarcinoma

```bibtex
@misc{secapidev_indications_pancreatic_ductal_adenocarcinoma_20261116,
  title        = {pancreatic ductal adenocarcinoma FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/pancreatic-ductal-adenocarcinoma}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_pancreatic_ductal_adenocarcinoma_20261116","title":"pancreatic ductal adenocarcinoma FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/pancreatic-ductal-adenocarcinoma","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
